The Cognalyzer® scans EEG (brainwaves) of consumers and leverages AI to quantify if a person is experiencing psychoactive effects.
MRX1 demonstrated “cardioprotective effects” in a pre-clinical study.
Cannaray Limited, its medical cannabis subsidiary Therismos, and Canadian ‘aquaponics’ cannabis cultivator Aqualitas are set to merge to create a new international vertically integrated cannabis company....
Script Assist's medical cannabis technology platform will now be available on a software as a service (SaaS) basis for the first time.
Lyphe is proud to announce the launch of its new low-cost medical cannabis line, Noidecs Vital, designed to address affordability issues for medical patients. Recognising the...
The first domestically grown medical cannabis is now available to patients in the UK.
Scientists at 113 Botanicals and the University of Sussex are developing new formulations for cannabis-based medicines.
The CRDG will set out the country’s first comprehensive strategy for cannabinoid research and development.
Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders.
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’...
